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Abstract
Background: Off-treatment durability of nucleoside analogue (NA) therapy in patients with chronic hepatitis B has
not been well investigated. In this study we monitored antiviral effect of NA therapy and evaluated off-treatment
durability after NA cessation in patients with chronic hepatitis B.
Patients and methods: A total of 94 consecutive patients (39 HBeAg-negative and 55 HBeAg-positive patients)
who received NA therapy were followed up for approximately 9 years. We discontinued NA according to the following
criteria; undetectable serum HBV-DNA by polymerase chain reaction (PCR) on three separate occasions at least 6 months
apart in HBeAg-negative patients (APASL stopping recommendation), and seroconversion from HBeAg-positive to
HBeAb-positive and undetectable serum HBV-DNA by PCR for at least 12 months in HBeAg-positive patients.
Results: The cumulative rate of relapse after NA cessation was 48 % and 40 % in HBeAg-negative and -positive patients,
respectively. Higher baseline serum alanine aminotransferase level was the only significant predictor for maintaining
remission. No patients experienced decompensation after relapse. HBsAg loss occurred at an annual rate of 1.4 % and
0.4 % in HBeAg-negative and -positive patients, respectively. Hepatocellular carcinoma developed at an annual rate of
0.6 % in both HBeAg-negative and -positive patients.
Conclusions: Almost half of the patients did not relapse after cessation of NA therapy in both HBeAg-negative
and -positive patients. Therefore, NA therapy could be discontinued with close monitoring if the APASL stopping
recommendation is satisfied even in HBeAg-negative patients.
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Background
Nucleoside analogues (NAs) are shown to improve prog-
nosis of patients with chronic hepatitis B. Continuous
treatment with lamivudine (LMV) delayed clinical pro-
gression defined by hepatic decompensation, hepatocellu-
lar carcinoma (HCC), spontaneous bacterial peritonitis,
bleeding gastroesophageal varices, or liver disease-related
death in patients with chronic hepatitis B and advanced fi-
brosis or cirrhosis [1]. NAs can suppress hepatic inflam-
mation by inhibiting viral proliferation in most cases,
however, this effect is transient. Relapse after NA cessation
is frequently observed [2–9]. Alanine aminotransferase
(ALT) flare with 10 times higher than normal upper limit
was reported in up to 20 % [2, 3] of patients who discon-
tinued NA treatment. These results suggest that NA dis-
continuation should be decided with caution. On the
other hand, considerable number of patients are receiving
NA treatment even if they actually no longer need NA.
Therefore, making a discrimination of patients who can
discontinue NA treatment is important from the view-
point of health care economics.
Currently there is no clear consensus on when to stop
NA treatment. For HBeAg-negative patients, the guide-
lines from the American Association for the Study of
Liver Diseases (AASLD) [10] and the European Associ-
ation for the Study of the Liver (EASL) [11] recommend
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long-term NA treatment until HBsAg seroclearance has
been achieved. Although HBsAg seroclearance is an
ideal goal of NA treatment, it takes place in only a mi-
nority of patients (<1 % per year [10]). On the other
hand, the Asian-Pacific Association for the Study of the
Liver (APASL) guideline [12] suggests that treatment
discontinuation can be considered if patients have been
treated for at least 2 years with undetectable HBV-DNA
documented on three separate occasions 6 months apart,
even if HBsAg seroclearance is not achieved. For HBeAg-
positive patients, the AASLD, EASL and APASL guide-
lines recommend that NA treatment can be discontinued
when HBeAg seroconversion with undetectable HBV-
DNA has been maintained for 6-12 months.
There have been several studies on off-treatment dur-
ability of NA’s antiviral effect (see review [13]), however,
the results considerably vary by study. Therefore, the ac-
cumulation of further data is required.
In this study we monitored antiviral effect of NA therapy
and evaluated off-treatment durability after NA cessation
according to the APASL stopping recommendation in
patients with chronic hepatitis B.
Methods
We consecutively enrolled the patients who started
treatment with LMV or entecavir (ETV) from December
1999 through June 2010. Most patients started with
ETV since ETV was approved in Japan (July 2006).
These patients were positive for serum HBsAg and
HBV-DNA, and had elevated ALT at least twice before
initiating treatment. We excluded patients who were co-
infected with HCV or HIV, and those with liver cirrhosis
or HCC. We discontinued NA treatment after obtaining
verbal informed consent when patients satisfied the
APASL stopping recommendation [12]; undetectable
serum HBV-DNA by polymerase chain reaction (PCR)
on three separate occasions at least 6 months apart in
HBeAg-negative patients, and seroconversion from
HBeAg-positive to HBeAb-positive and undetectable
serum HBV-DNA by PCR for at least 12 months in
HBeAg-positive patients. Treatment for at least 2 years
was not a prerequisite for NA discontinuation in this
study. Patients were followed up every one to three
months to monitor blood chemistry and HBV markers.
They received ultrasonography for the surveillance of
HCC every 6 months. Relapse after NA discontinuation
was defined as serum ALT elevation more than twice
the upper limit of normal or serum HBV-DNA elevation
higher than 5 log copy/mL at 2 consecutive examina-
tions. Serum HBV-DNA levels were measured by
COBAS TaqMan HBV test (Roche Molecular Systems,
Inc., Pleasanton, CA). Serum HBsAg was quantitated by
Architect assay (Abbott Japan, Co., Ltd., Tokyo, Japan). A
part of serum samples were stored at −80°C until
measurement. This study had been approved by Institu-
tional Review Board for Clinical Research, Tokai University
Hospital, and was performed in accordance with the Dec-
laration of Helsinki.
Statistical analysis
Pearson chi-square and Fisher exact probability tests were
performed to compare the frequency distributions of
categorical variables between groups. One-way analysis of
variance was used to test the differences in means between
groups for continuous variables. The probabilities of satis-
fying NA discontinuation criteria, relapse, disappearance
of serum HBsAg, and progression to HCC were estimated
using the Kaplan-Meier method, and differences between
groups were compared using the log-rank test. Analyzed
baseline factors included age, gender, HBV genotype,
serum ALT, HBV-DNA, HBsAg, and liver histology
assessed by METAVIR classification [14]. The factors with
P value < .1 by univariate analysis were evaluated with a
Cox proportional hazards regression model. All statistical
analyses were performed using SPSS version 22 (SPSS
Japan, Tokyo, Japan). All reported P values are 2-sided,
with P < .05 considered statistically significant.
Results
Patient characteristics
The cohort consisted of 94 patients; 39 and 55 patients
were negative and positive for HBeAg, respectively (Table 1).
The HBeAg-negative patients were significantly older than
the HBeAg-positive patients. Most patients were infected
with genotype C HBV (84 % and 97 % in HBeAg-
negative and -positive patients, respectively). The serum
HBV-DNA levels were significantly higher in the
HBeAg-positive patients. The mean ± SD of the follow-
up period was 108 ± 42 (min-max: 18-182) and 111 ± 42
(min-max: 16-178) months in HBeAg-negative and -positive
patients, respectively.
Outcome of the patients
HBeAg-negative patients
Twenty-five (64 %) patients received LMV, while the
remaining 14 (36 %) received ETV (Fig. 1). Most of the pa-
tients (23/25, 92 %) receiving LMV met the APASL stopping
recommendation. Of 23 patients 17 agreed to stop LMV
treatment, and 10 of these 17 patients (59 %) maintained
remission. In 7 patients who relapsed, 3 achieved remis-
sion afterwards and 4 started ETV treatment. All of 14
patients (100 %) receiving ETV met the stopping criteria.
Six of 14 patients agreed to stop ETV treatment, and 2
of 6 (33 %) maintained remission. In 4 relapsers, 2
achieved remission afterwards, and 2 restarted ETV. The
mean ± SD of NA treatment duration until discontinu-
ation was 40 ± 41 (min-max: 8–141) and 26 ± 17 (min-
max: 9–50) months in patients who received LMV and
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ETV, respectively. The difference between LMV and
ETV was not statistically significant. A total of 11 pa-
tients (48 %) experienced relapse. Most relapses oc-
curred within 1 year after NA cessation. The cumulative
relapse rate at 1 year, 2 years, and 5 years were 30 %, 35 %,
and 39 %, respectively. In contrast, 44 % of patients were
under control without NA administration.
HBeAg-positive patients
Thirty-eight (69 %) patients received LMV and the
remaining 17 (31 %) received ETV (Fig. 2). In patients
who received LMV, 13 patients (34 %) met the stopping
criteria. Six (60 %) of 10 patients who consented to stop
LMV maintained remission. The mean ± SD of treatment
duration until discontinuation was 44 ± 23 (min-max: 15–86)
months. In 4 relapsers, 2 achieved remission afterwards,
while 2 restarted ETV. Only 2 of 17 who received ETV
met stopping criteria, and both continued ETV treatment.
Finally, 4 patients (40 %) relapsed. The 1-year, 2-year, and
5-year cumulative relapse rates were 20 %, 30 %, and 30 %,
respectively, whereas 15 % of patients were under control
without NA administration.
Predictive factors for meeting the stopping criteria
HBeAg-negative patients were more likely to meet the
stopping criteria than HBeAg-positive patients (95 % vs.
27 %, P < 0.001, Fig. 3). We analyzed the predictive fac-
tors for meeting the stopping criteria in HBeAg-positive
patients. Multivariate analysis revealed lower serum
HBV-DNA level as the only predictive factor (P = 0.02).
The proportion of patients who met the stopping criteria
was 42 % (10/24) in those with serum HBV-DNA of 7.6
Table 1 Patient characteristics
Variables HBeAg (-) (n=39) HBeAg (+) (n=55) P value
no. % no. %
Age, <40/40-59/60≤ 7/22/10 18/56/26 22/23/10 40/42/18 0.07
Age (y/o) 50.0 ± 11.8 44.3 ± 14.5 0.03
Gender, female/male 11/28 28/72 18/37 33/67 0.7
Drug, LAM/ETV 25/14 64/36 38/17 69/31 0.7
ALT (IU/L), <100/100-199/200≤ 12/16/11 31/41/28 20/13/22 36/24/40 0.19
HBV-DNA (Log copy/mL), <6/6-7.6/7.6< 11/22/6 28/56/15 4/20/31 7/36/56 0.001
Genotype*, B/C 5/26 16/84 1/37 3/97 0.07
HBsAg (IU/mL)*, <1000/1000-10000/10000≤ 7/11/5 30/48/22 3/9/8 15/45/40 0.09
Histology (METAVIR Staging)*, 1/2/3 13/8/6 48/30/22 11/13/7 35/42/23 0.6
Histology (METAVIR Grading)*, 1/2/3 7/17/3 26/63/11 8/15/8 26/48/26 0.3
*Data were not available in some patients
Fig. 1 Flow chart of HBeAg-negative patients. LMV: lamivudine, ETV: entecavir, ADV: adefovir
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log copy/mL or less, whereas it was 15 % (5/31) in those
with serum HBV-DNA higher than 7.6 log copy/mL.
Predictive factors for relapse
A total of 15 (45 %) among 33 patients who discontinued
NA treatment relapsed, while the remaining 18 (55 %)
maintained remission. We analyzed the baseline variables
associated with relapse. Multivariate analysis demon-
strated that serum ALT was the only predictive factor
for relapse. Relapse rate was 50 % (2/4), 71 % (10/
14), and 20 % (3/15) in patients with ALT < 100, 100–
199, and ≥ 200 IU/mL, respectively. The patients with
ALT ≥ 200 IU mL were more likely to maintain remission
(Fig. 4, P = 0.02).
Fig. 2 Flow chart of HBeAg-positive patients. LMV: lamivudine, ETV: entecavir, ADV: adefovir
Fig. 3 Cumulative rate of satisfying NA stopping criteria according to the HBeAg status
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Serum ALT elevated up to more than 500 IU/mL in 4
of 15 relapsers (27 %), however, none experienced
decompensation.
HBsAg disappearance
Serum HBsAg disappeared in 7 patients (7.4 %), resulting
in an annual HBsAg disappearance rate of 0.8 %; 1.4 %
and 0.4 % for HBeAg-negative and -positive patients, re-
spectively. We analyzed the baseline factors associated
with HBsAg loss. Serum HBV-DNA was the only predict-
ive variable by multivariate analysis; HBsAg loss was
observed in 5 of 15 patients (33 %) with serum HBV-DNA
less than 6 log copy/mL, while 2 of 79 patients (3 %) with
serum HBV-DNA of 6 log copy/mL or higher (P = 0.001).
The accumulated HBsAg loss was observed more fre-
quently in those with lower HBV-DNA (Fig. 5, P = 0.02).
HCC progression
Five of 94 (5.3 %) patients progressed to HCC, resulting
in an annual HCC progression rate of 0.6 % in both
HBeAg-negative and -positive patients. Age was the only
predictive variable for HCC progression by multivariate
analysis (P = 0.01). Only one of 74 (1.4 %) patients youn-
ger than 60 years progressed to HCC, whereas did 4 of
20 (20 %) patients aged 60 or older (P = 0.01, Fig. 6).
Four patients died, all of whom were HBeAg-positive.
One died of HCC and the remaining 3 died of the dis-
eases unrelated to the liver (pancreatic cancer, gastric
cancer, and unknown).
Discussion
In approximately 9 years after initiating NA administra-
tion, 44 % (17/39) of HBeAg-negative patients and 15 %
(8/55) of HBeAg-positive patients were under control
without NA. In other words, more than half of HBeAg-
negative and most of HBeAg-positive patients still need
NA therapy, suggesting difficulty in stopping NA therapy.
In this study we adopted the APASL stopping recom-
mendation [12]. Most of the HBeAg-negative patients
(95 %) satisfied this stopping criteria, whereas only one
forth of the HBeAg-positive patients (27 %) did. These
results are in agreement with a study [15] reporting that
seroconversion from HBeAg-positive to HBeAb-positive
occurred only in 38 % of HBeAg-positive patients
through 4 year-treatment of ETV. Multivariate analysis
revealed that patients with lower serum HBV-DNA
levels were more likely to meet the stopping criteria in
concordance with the previous study [15]. Thus, patients
with higher serum HBV-DNA will have difficulty to
cease NA treatment once it started.
In HBeAg-negative patients, the cumulative relapse
rate after discontinuation of NA therapy was 48 % (11/
23), which was comparable with the previous studies [9,
16-19]. Jeng et al. [19] evaluated off-therapy durability in
95 patients who discontinued ETV treatment according
to the APASL stopping recommendation as we adopted.
The cumulative 1-year relapse rate was 45.3 %. On the
other hand, another prospectively study [20] enrolling
184 patients in which ETV was stopped according to the
APASL stopping recommendation demonstrated an
Fig. 4 Cumulative rate of relapse after NA discontinuation according to the serum ALT levels
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exceptionally high cumulative 1-year relapse rate of 91.4
%. Although reason for the discrepancy in the reported
relapse rates is unclear, the differences in patients back-
ground and study design may be involved. The AASLD
and EASL recommend long-term NA therapy until
HBsAg seroclearance is achieved, however, this goal is
unrealistic considering very low HBsAg seroclearance
rate (<1 % per year [10]). The others and we showed
that approximately half of the HBeAg-negative
patients remained remission after cessation of NA
therapy according to the APASL stopping recommen-
dation. Thus, NA therapy can be stopped with proper
monitoring.
In the HBeAg-positive patients, cumulative relapse rate
after discontinuation of NA therapy was 40 % (4/10), which
is in concordance with other studies ranging 29–77 %
Fig. 5 Cumulative rate of HBsAg loss according to the viral load
Fig. 6 Cumulative rate of HCC occurrence according to the age
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[5, 6, 8, 20-24]. According to a retrospective study of
Song et al. analyzing 98 HBeAg-positive patients who
stopped LMV therapy after HBeAg seroconversion,
the cumulative relapse rates at 1 year and 2 years
were 37.5 % and 49.2 %, respectively [5].
Our study demonstrated that relapse was less frequently
observed in patients with higher ALT levels in agreement
with a previous study [6]. Patients with high ALT indicat-
ing strong immunological reaction against HBV may be
on the transition state from immune clearance phase to
low replicative phase in which relapse is relatively rare.
Although lower baseline serum HBV-DNA [5, 6, 19] and
younger age [9, 25–27], and longer treatment duration
[5, 27] were associated with lower relapse rate in other
studies, we could not find these associations.
Four of 15 relapsers (27 %) underwent serum ALT
flare above 500 IU/L, however, they did not progress to
liver failure. ALT flare with 10 times higher than normal
upper limit was reported in up to 20 % [2, 3] of patients
who discontinued NA treatment. We similarly observed
ALT flare, but did not experience decompensation as
previous studies [9, 19, 20, 22].
HBsAg disappeared at an annual rate of 0.8 %; 1.4 % in
HBeAg-negative and 0.4 % in HBeAg-positive patients.
These results are compatible with other studies [28-32].
Low baseline serum HBV-DNA was the only predictor for
HBsAg disappearance in our study, in agreement with a
previous study [33]. Kim et al. [33] revealed 0.33 % annual
HBsAg seroclearance rate by 6-year-follow-up of 5409
patients (two-thirds were HBeAg positive) receiving LMV
or ETV therapy, and demonstrated baseline low HBV-
DNA, high ALT, HBeAg negativity, and absence of cirrho-
sis as predictors for HBsAg loss.
The progression to HCC was observed at an annual
rate of 0.6 % in both HBeAg-negative and -positive
patients, which results are in agreement with previous
studies [33-36]. The decrease of HCC occurrence by
long-term NA treatment is confirmed by a random-
ized study [1] and a meta-analysis [37]. The only
predictive factor for HCC progression was age of 60
years or older, which is also reported in a previous
study [36].
This study has limitations; the study was conducted in
a retrospective manner in a single institution, and num-
ber of patients was small. Our patients predominantly
consisted of genotype C. However, the data on off-
treatment durability of NA’s antiviral effect are still in-
sufficient, and we believe our results provide important
information.
Conclusions
Approximately half of the patients did not relapse after ces-
sation of NA therapy in both HBeAg-negative and -positive
patients. The relapsers did not experience decompensation.
Therefore, NA therapy could be discontinued with close
monitoring if the APASL stopping recommendation is sat-
isfied even in HBeAg-negative patients.
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